LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma has recently initiated a strategic initiative aiming to transform data management and informatics for the research organization. The transformation will promote innovation, enhance efficiency and increase the confidence in decisions throughout research, resulting in more innovative products brought faster to the patients. The collaboration with grit42 will enable this transformation.
“We see a great potential in applying state-of-the-art data management and data integration to leverage our R&D activities and improve our decision making. To strengthen these capabilities, we selected grit42 as our strategic software partner after a thorough evaluation against various competing solutions and we are excited about the impact that this collaboration can offer.” states Thorsten Thormann, Vice President of Research at LEO Pharma.
“Through 15 years of anthropological observations in pre-clinical drug discovery labs, we literally understand the specific workflows that our customers do, which in turn enables us to make the ideal software to support them“, states CEO of grit42, Claus Stie Kallesøe, and continues, “Now signing up to be a strategic partner with LEO Pharma validates our approach, and we look forward to rolling out our software across all the different phases of the drug discovery process, from in vitro and in vivo, to ADME and safety toxicology.”
Copenhagen-based grit42 focuses on research and lab informatics software for pre-clinical drug discovery. After having worked together for 15 years as the internal research informatics department at a Danish pharmaceutical company, grit42 launched in 2014. Read more at http://www.grit42.com